NDA 022186 · Long Grove Pharms
Ak-Fluor 25%
Fluorescein Sodium · Intravenous
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Aug 8, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
106
19 Phase 3, 6 recruiting
FAERS reports
240
197 serious, 15 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 26, 2026.
AK-FLUOR ® 10% (100 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. AK-FLUOR is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. ( 1 )
Mechanism: Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465 to 490 nm and fluoresces, i.e., emits light at wavelengths of 520 to 530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 8, 2008 Original approval · Type 3 - New Dosage Form ReviewSummary ReviewLetter
2 products under this application
- AK-FLUOR 25% · FLUORESCEIN SODIUM EQ 500MG BASE/2ML (EQ 250MG BASE/ML) · INJECTABLE, INTRAVENOUS · Discontinued · TE AP
- AK-FLUOR 10% · FLUORESCEIN SODIUM EQ 500MG BASE/5ML (EQ 100MG BASE/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluorescein" as an intervention, any sponsor and status, largest first.
- Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel BlockagePivotal-lookingCompleted
National Eye Institute (NEI)NIH
NCT00106132 · 1,260 participants · Start Mar 2005
Drug: Triamcinolone Acetonide · For: Retinal Vein Occlusion; Macular Edema, Cystoid; Macular Edema
Sites: Bethesda, Maryland
BayerBayer (BAYRY)
NCT05850520 · 892 participants · Start May 15, 2023 · Primary completion Nov 7, 2024
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose; Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg and 1 more · For: Macular Edema Secondary to Retinal Vein Occlusion
Sites: Fullerton, California; Long Beach, California; Mountain View, California · 273 sites in all
- Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric ParticipantsPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01959243 · 507 participants · Start Feb 22, 2014 · Primary completion Apr 23, 2014
Drug: Brimonidine Tartrate; Vehicle and 2 more · For: Hyperemia
Sites: Phoenix, Arizona; Havre de Grace, Maryland; Andover, Massachusetts · 4 sites in all
- Rose Bengal Electromagnetic Activation With Green Light for Infection ReductionPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT05110001 · 330 participants · Start Aug 3, 2022 · Primary completion Dec 14, 2024
Drug: Moxifloxacin Ophthalmic; Chlorhexidine Gluconate and 2 more · For: Acanthamoeba Keratitis; Fungal Keratitis
Sites: São Paulo, Brazil; Madurai, India
- Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal NeovascularizationPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00436553 · 321 participants · Start Feb 2007 · Primary completion Oct 2009
Drug: Verteporfin Photodynamic Therapy; Ranibizumab and 2 more · For: Macular Degeneration; Choroidal Neovascularization
Sites: Tucson, Arizona; Beverly Hills, California; Oakland, California · 43 sites in all
- Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)Pivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00433017 · 255 participants · Start May 2007 · Primary completion Jul 2009
Drug: Verteporfin Photodynamic Therapy; Ranibizumab and 1 more · For: Macular Degeneration; Choroidal Neovascularization
Sites: Vienna, Austria; Antwerp, Belgium; Aalborg, Denmark · 12 sites in all
- Central Catheters Used for Chemotherapy in Women With Breast CancerPivotal-lookingCompleted
Swedish Red Cross University CollegeAcademic, hospital or other
NCT04324346 · 250 participants · Start Apr 1, 2016 · Primary completion Feb 1, 2021
Drug: FEC75 (or EC90) x 6; FEC100 + Taxotere (EC90 + Taxotere) 3+3 and 1 more · For: Catheter Related Complications
Sites: Stockholm, Sweden
Technical University of MunichAcademic, hospital or other
NCT04597801 · 210 participants · Start Dec 30, 2020 · Primary completion Jun 17, 2022
Drug: Alcon · For: Intracranial Tumor
Sites: Mannheim, Germany; München, Germany; Regensburg, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- visual acuity reduced31
- nausea25
- urticaria16
- anaphylactic reaction15
- headache15
- pruritus15
- dizziness13
- drug hypersensitivity13
- vomiting13
- dyspnoea12
- retinal haemorrhage12
- hyperhidrosis10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 12 |
| 2006 | 5 |
| 2007 | 1 |
| 2008 | 5 |
| 2009 | 34 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 9 |
| 2015 | 14 |
| 2016 | 26 |
| 2017 | 23 |
| 2018 | 14 |
| 2019 | 15 |
| 2020 | 12 |
| 2021 | 7 |
| 2022 | 9 |
| 2023 | 6 |
| 2024 | 12 |
| 2025 | 6 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dry eye post-cataract surgery: a systematic review and meta-analysis.
Ta H, McCann P, Xiao M, et al. · BMC Ophthalmol 2025 · Systematic Review, Meta-Analysis
- Clinical evaluation of tear substitute utility after anti-VEGF intravitreal injection.
Carlo C, Poddi M, Mocini S, et al. · Eur J Ophthalmol 2024 · Randomized Controlled Trial
- Evaluation of corneal staining with an antihistamine-releasing contact lens.
Pall B, Sun CK · Clin Exp Optom 2023 · Randomized Controlled Trial
- Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction.
Cote S, Zhang AC, Ahmadzai V, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Auricular Acupressure for Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Huang Q, Zhan M, Hu Z · Medicina (Kaunas) 2023 · Meta-Analysis, Systematic Review
- Therapeutic Effect of Intense Pulsed Light on Ocular Demodicosis.
Zhang X, Song N, Gong L · Curr Eye Res 2019 · Comparative Study, Randomized Controlled Trial
Sponsor: Long Grove Pharms · Also marketed as Ak-Fluor 10%
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.